NCT00119730 - Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2013

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Fludarabine

Given on days 1-3 of each 28-day cycle

DRUG

Mitoxantrone

Given on day 1 of each 28-day cycle

DRUG

Rituximab

Given on day 1 of each 28-day cycle

DRUG

Zevalin

After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston